Print

Purpose

To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Male/female patients who are at least 18 years of age on the day of informed consent signing. 2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy. 3. Provision of written informed consent for the study. 4. Pregnant women not included 5. Cognitively impaired adults are not included.

Exclusion Criteria

None

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Diagnostic
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Other
cell-free DNA (cfDNA) samples 		cell-free DNA (cfDNA) samples from DLBCL participants before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method. Blood will be drawn 3 times (by vein)
  • Diagnostic Test: cell-free DNA
    Given by IV (vein)

Recruiting Locations

Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
San Antonio, Texas 78229
Contact:
Adolfo Enriques Diaz Duque, MD
210-450-1209
diazduque@uthscsa.edu

More Details

Status
Recruiting
Sponsor
M.D. Anderson Cancer Center

Study Contact

Christopher Flowers, MD
(713) 745-6095
crflowers@mdanderson.org

Detailed Description

Primary Objective: • To determine the feasibility and clinical utility of ctDNA in identifying actionable alterations and minimal residual disease for lymphoma patients across community centers in Texas. Secondary Objectives: - To provide useful prognostic information before treatment, assess molecular response at interim time points and residual disease at the end of therapy, and identify tumor-specific mutations - Levels of cfDNA and its association with both EFS and OS in patients receiving therapy

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.